New Delhi: A day after Prime Minister Narendra Modi’s speech at the United Nations General Assembly, the Executive Director of the Serum Institute of India, Adar Poonawalla, said on Sunday (September 27, 2020) that it was clear that the first Minister had made ‘arrangements’ for India. citizens who will take care of all the needs of the people.
Applauding Prime Minister Modi’s vision of providing vaccines to the global community, Poonawalla said it was a proud moment for India.
On the microblogging site Twitter, he wrote: “We share and applaud your vision @narendramodi ji, on supplying vaccines to the global community. It is a proud moment for India, thank you for your leadership and support. arrangements because India will take care of all the needs of the Indian people. “
We share and applaud your vision @Narendra Modi hee, about supplying vaccines to the world community. It is a proud moment for India, thank you for your leadership and support. It is clear that all your arrangements for India will take care of all the needs of the Indian people. https://t.co/b57TH8fDSB
– Adar Poonawalla (@adarpoonawalla) September 27, 2020
Earlier on Saturday, the 39-year-old, in another tweet, had asked the Center if they had Rs 80 billion available over the next year for the distribution of COVID-19 vaccines throughout India.
On live Tv
He had written: “Quick question: will the government of India have Rs 80 billion available in the next year? Because that is what the Ministry of Health needs, to buy and distribute the vaccine to everyone in India. This is the next related challenge we have to tackle. “
In an interview, Adar Poonawalla had expressed that the availability of the vaccine even for 90% of all the people of the planet will not be possible before 2024. “Realistically, for everyone, for everyone on this planet, or at minus 90% to achieve it, it will be at least 2024 “, he had said.
The Pune-based Serum Institute of India (SII) is the world’s largest vaccine manufacturing company and is licensed to produce and market two of the leading candidate vaccines, one developed by AstraZeneca and the University of Oxford, and the other by the American company Novavax.
The University of Oxford vaccine, called Covishield in India, is currently in phase II and III trials in the country. Previously, the institute had announced that it would make the $ 3 Oxford vaccine available to low- and middle-income countries, including India.
.
